Last reviewed · How we verify
Rapid-acting insulin secretagogue — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Rapid-acting insulin secretagogue (Rapid-acting insulin secretagogue) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rapid-acting insulin secretagogue TARGET | Rapid-acting insulin secretagogue | Takeda | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rapid-acting insulin secretagogue CI watch — RSS
- Rapid-acting insulin secretagogue CI watch — Atom
- Rapid-acting insulin secretagogue CI watch — JSON
- Rapid-acting insulin secretagogue alone — RSS
Cite this brief
Drug Landscape (2026). Rapid-acting insulin secretagogue — Competitive Intelligence Brief. https://druglandscape.com/ci/rapid-acting-insulin-secretagogue. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab